# US 2013/0251664 A1 · 1L1RL-1 as a Cardiovascular Disease Marker and Therapeutic Target

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0251664 A1
- Document ID: US20130251664A1
- Status: Published application
- Kind: A1
- Application number: 13/789,941
- Filed: 2013-03-08
- Published: 2013-09-26
- Earliest claimed: 2002-05-09
- Assignees: The Brigham and Women's Hospital, Inc.
- Applicants: The Brigham and Women's Hospital, Inc.
- Inventors: Richard T. Lee
- Web page: https://patentgrep.com/patent/US20130251664A1

## CPC

- G01N 33/6869: {Interleukin}
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C12Q 1/6883: for diseases caused by alterations of genetic material
- G01N 33/6893: {related to diseases not provided for elsewhere}
- A61K 39/00112: {Receptors for interferons [IFN]}
- C12Q 2600/106: Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C12Q 2600/156: Polymorphic or mutational markers
- C12Q 2600/158: Expression markers
- G01N 2333/7155: for interleukins [IL]
- G01N 2800/2871: Cerebrovascular disorders, e.g. stroke, cerebral infarct, cerebral haemorrhage, transient ischemic event
- G01N 2800/32: Cardiovascular disorders
- G01N 2800/324: Coronary artery diseases, e.g. angina pectoris, myocardial infarction
- G01N 2800/325: Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- Y02A 90/10: Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

This invention pertains to methods and compositions for the diagnosis and treatment of cardiovascular conditions. More specifically, the invention relates to isolated molecules that can be used to diagnose and/or treat cardiovascular conditions including cardiac hypertrophy, myocardial infarction, stroke, arteriosclerosis, and heart failure.

## Claims

### Claim at position 1

1-33. (canceled)

### Claim 34

A method for evaluating the likelihood that a subject will benefit from treatment with an agent for reducing the risk of a cardiovascular condition and treating the subject, the method comprising:
(a) performing an assay to determine a level of soluble ST2 in a sample from a subject having or suspected of having a cardiovascular condition;
(b) comparing the level of soluble ST2 in the sample to a predetermined value;
(c) identifying a subject having an elevated level of soluble ST2 compared to the predetermined value as having an increased likelihood of benefiting from treatment with an agent for reducing the risk of a cardiovascular condition; and
(d) administering an agent for reducing the risk of a cardiovascular condition to the subject identified in (c).

### Claim 35 (depends on 34)

The method of claim 34, wherein the agent is selected from the group consisting of: an anti-inflammatory agent, an anti-thrombotic agent, an anti-platelet agent, a fibrinolytic agent, a lipid-reducing agent, a direct thrombin inhibitor, a glycoprotein IIb/IIIa receptor inhibitor, a calcium channel blocker, a beta-adrenergic receptor blocker, a cyclooxygenase-2 inhibitor, and a renin-angiotensin system (RAS) inhibitor.

### Claim 36 (depends on 35)

The method of claim 35, wherein the agent is a lipid-reducing agent.

### Claim 37 (depends on 36)

The method of claim 36, wherein the lipid-reducing agent is selected from the group consisting of: gemfibrozil, cholystyramine, colestipol, nicotinic acid, probucol, lovastatin, fluvastatin, simvastatin, atorvastatin, pravastatin, and cerivastatin.

### Claim 38 (depends on 35)

The method of claim 35, wherein the renin-angiotensin system (RAS) inhibitor is selected from the group consisting of: an angiotensin-converting enzyme (ACE) inhibitor, an angiotensin II receptor blocker (ARB), an angiotensin II receptor antagonist, an agent that activates the catabolism of angiotensin II, and an agent that prevents the synthesis of angiotensin I.

### Claim 39 (depends on 34)

The method of claim 34, wherein the cardiovascular condition is selected from the group consisting of: cardiac hypertrophy, myocardial infarction, stroke, and heart failure.

### Claim 40 (depends on 34)

The method of claim 34, wherein the assay in (a) is performed using an antibody that specifically binds to soluble ST2.

### Claim 41 (depends on 34)

The method of claim 34, wherein the predetermined value is a plurality of predetermined marker level ranges and said comparing in (b) comprises determining in which of said predetermined marker ranges the subject's level falls.

### Claim 42 (depends on 34)

The method of claim 34, wherein the sample comprises a biological fluid.

### Claim 43 (depends on 42)

The method of claim 42, wherein the biological fluid is blood or serum.

### Claim 44 (depends on 34)

The method of claim 34, further comprising determining the level of at least one other marker related to a cardiovascular condition.

### Claim 45 (depends on 44)

The method of claim 44, wherein the at least one marker is selected from the group consisting of: a circulating catecholamine, angiotensin II, creatine, creatine kinase MB isoenzyme, C-reactive protein, a troponin, a natriuretic peptide, and a marker of oxidative stress.

### Claim 46 (depends on 45)

The method of claim 45, wherein the at least one marker is a troponin or a brain natriuretic peptide.

### Claim 47 (depends on 45)

The method of claim 45, wherein the troponin is cardiac troponin I.

### Claim 48 (depends on 45)

The method of claim 45, wherein the circulating catecholamine is norephinephrine, domaine, or epinephrine.

### Claim 49 (depends on 45)

The method of claim 45, wherein the natriuretic peptide is a brain natriuretic peptide (BNP) or pro-atrial natriuretic peptide (ProANP).

### Claim 50 (depends on 49)

The method of claim 49, wherein the natriuretic peptide is a BNP.

### Claim 51 (depends on 45)

The method of claim 45, wherein the marker of oxidative stress is adrenolutin or malondialdehyde.

### Claim 52 (depends on 34)

The method of claim 34, wherein the subject is suspected of having a cardiovascular condition.
